EFFERVA

Serial Number 88824652
606

Registration Progress

Application Filed
Mar 6, 2020
Under Examination
Aug 25, 2020
Approved for Publication
Jun 30, 2020
Published for Opposition
Jun 30, 2020
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: EFFERVA
Previous Owner: Aquestive Therapeutics, Inc.
Classes: 005

Trademark Image

EFFERVA

Basic Information

Serial Number
88824652
Filing Date
March 6, 2020
Published for Opposition
June 30, 2020
Abandonment Date
September 25, 2023
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Sep 25, 2023
Classes
005

Rights Holder

Aquestive Therapeutics, Inc.

03
Address
30 Technology Drive
Warren, NJ 07059

Ownership History

Aquestive Therapeutics, Inc.

Original Applicant
03
Warren, NJ

Aquestive Therapeutics, Inc.

Owner at Publication
03
Warren, NJ

Legal Representation

Attorney
Catherine Dugan O'Connor

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

35 events
Date Code Type Description Documents
Sep 25, 2023 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Sep 25, 2023 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Feb 9, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 8, 2023 EX5G S SOU EXTENSION 5 GRANTED Loading...
Jan 23, 2023 EXT5 S SOU EXTENSION 5 FILED Loading...
Feb 8, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jan 23, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 25, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Aug 25, 2022 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Aug 25, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Aug 25, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jul 28, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 26, 2022 EX4G S SOU EXTENSION 4 GRANTED Loading...
Jul 26, 2022 EXT4 S SOU EXTENSION 4 FILED Loading...
Jul 26, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 5, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 3, 2022 EX3G S SOU EXTENSION 3 GRANTED Loading...
Feb 3, 2022 EXT3 S SOU EXTENSION 3 FILED Loading...
Feb 3, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 31, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 29, 2021 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jul 29, 2021 EXT2 S SOU EXTENSION 2 FILED Loading...
Jul 29, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 28, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jan 26, 2021 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jan 26, 2021 EXT1 S SOU EXTENSION 1 FILED Loading...
Jan 26, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 25, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 30, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 30, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 10, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 27, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 27, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 12, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 10, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the prevention and treatment of neurological, cardiopulmonary, viral, metabolic, endocrine, musculoskeletal, genitourinary, gastrointestinal, oncological, autoimmune, inflammatory, pain, respiratory, hormonal, and psychiatric related diseases and disorders; pharmaceutical preparations for treatment of sexual dysfunction; pharmaceutical preparations for prevention of sexual dysfunction; Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular system, hypertension, and pulmonary arterial hypertension; pharmaceutical preparations for the treatment of benign prostatic hyperplasia; pharmaceutical preparations for the treatment of migraine, tension, and cluster headaches; pharmaceutical preparations for the treatment of epilepsy

Classification

International Classes
005